Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccineRebecca Payne, Victoria Hall, Wanwisa Dejnirattisai et al.|Cell|2021Cited by 352
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R. Barrett, Catherine Green, Sandra Belij‐Rammerstorfer et al.|Nature Medicine|2020Cited by 340